Blab Business
PetVivo Holdings Announces Virtual Investor Event on June 16 to Discuss Veterinary Product Expansion
On Tuesday, June 16, 2026, PetVivo Holdings invites investors to a virtual gathering that promises to unveil how veterinarians are embracing its cutting‑edge products and how the company plans to widen access across the pet‑care market.
The 1 p.m. Eastern Time session, titled "What Veterinarians Are Seeing and How Access Is Expanding," will be streamed live on YouTube and LinkedIn and is designed for both new and existing shareholders. A moderator will guide a discussion featuring three key company voices: John Lai, CEO, President and Director of PetVivo Holdings; Dr. Juli Goldstein, DVM, CHPV, a veterinarian and core member of the PetVivo team; and Bryan Monninger, Vice President of Sales and Distributor Relations.
PetVivo, a rising name in biomedical devices, operates through its wholly‑owned subsidiaries PetVivo Animal Health, Inc. and PetVivo AI, Inc. The firm focuses on manufacturing, commercializing, and licensing innovative medical devices and therapeutics for companion animals and equines. By adapting human therapies for animal use, PetVivo seeks to capitalize on the faster market entry of veterinary medical devices compared with heavily regulated pharmaceuticals.
Central to the company’s portfolio is Spryng® with OsteoCushion® Technology, a veterinarian‑administered intra‑articular injection that treats lameness and joint‑related conditions such as osteoarthritis in cats, dogs, and horses. Spryng® is already available for commercial sale. PetVivo also markets PrecisePRP®, a first‑in‑class off‑the‑shelf platelet‑rich plasma (PRP) product intended for veterinary use.
The firm’s pipeline is protected by twelve patents and six trade secrets that cover biomaterials, products, production processes, and methods of use. PetVivo emphasizes an accelerated revenue timeline for its veterinary devices, which can reach the market earlier than more heavily regulated biologics.
According to the company’s press release, the investor event will focus on how veterinarians are responding to Spryng® and PrecisePRP®, and on the company’s strategy to broaden access through new sales and distribution partnerships. The event is part of PetVivo’s broader investor‑relations program, which also includes quarterly earnings calls and product‑development updates.
Contact information for the event is provided in the release: John Lai can be reached at (952) 405‑6216. Additional details are available on the company’s websites—petvivo.com, petvivoanimalhealth.com, and sprynghealth.com.
PetVivo issued a forward‑looking statement in the release, noting that any statements about future plans, timelines, or expectations are subject to risks and uncertainties. The company referenced its annual report on Form 10‑K for the year ended March 31, 2025, for a discussion of those risks.
Investors who wish to view the event can access the live stream on YouTube at https://www.youtube.com/live/QLFfsfCpE1U?si=ItU-PWgNUKsQ2tkQ and on LinkedIn at https://www.linkedin.com/events/7466155223904890880?viewAsMember=true. Additional company information, financial materials, and updates are available through the investor relations portal at https://www.petvivo.com/investors.
The virtual event falls on the same day as the company’s other investor‑relations activities, including a conference call for the fiscal third quarter of 2026 on Monday, February 16, 2026, and a presentation at the Market Movers Investor Summit on May 5, 2026. These events provide context for the company’s recent financial performance, which has shown growth in revenue and strategic expansion of its product line.
In summary, PetVivo Holdings is using the June 16 virtual event to give investors a detailed look at how its veterinary products are being received in the field and how the company plans to increase market penetration. The event will also highlight the company’s broader strategy of leveraging human‑derived therapies for animal health and its ongoing efforts to secure new distribution channels.
The company’s next public disclosure will likely come in the form of its fiscal third‑quarter earnings report, scheduled for release in the coming weeks. Investors will also be watching for any updates on regulatory approvals, new product launches, and potential partnership announcements that could influence the company’s valuation and market position.
The 1 p.m. Eastern Time session, titled "What Veterinarians Are Seeing and How Access Is Expanding," will be streamed live on YouTube and LinkedIn and is designed for both new and existing shareholders. A moderator will guide a discussion featuring three key company voices: John Lai, CEO, President and Director of PetVivo Holdings; Dr. Juli Goldstein, DVM, CHPV, a veterinarian and core member of the PetVivo team; and Bryan Monninger, Vice President of Sales and Distributor Relations.
PetVivo, a rising name in biomedical devices, operates through its wholly‑owned subsidiaries PetVivo Animal Health, Inc. and PetVivo AI, Inc. The firm focuses on manufacturing, commercializing, and licensing innovative medical devices and therapeutics for companion animals and equines. By adapting human therapies for animal use, PetVivo seeks to capitalize on the faster market entry of veterinary medical devices compared with heavily regulated pharmaceuticals.
Central to the company’s portfolio is Spryng® with OsteoCushion® Technology, a veterinarian‑administered intra‑articular injection that treats lameness and joint‑related conditions such as osteoarthritis in cats, dogs, and horses. Spryng® is already available for commercial sale. PetVivo also markets PrecisePRP®, a first‑in‑class off‑the‑shelf platelet‑rich plasma (PRP) product intended for veterinary use.
The firm’s pipeline is protected by twelve patents and six trade secrets that cover biomaterials, products, production processes, and methods of use. PetVivo emphasizes an accelerated revenue timeline for its veterinary devices, which can reach the market earlier than more heavily regulated biologics.
According to the company’s press release, the investor event will focus on how veterinarians are responding to Spryng® and PrecisePRP®, and on the company’s strategy to broaden access through new sales and distribution partnerships. The event is part of PetVivo’s broader investor‑relations program, which also includes quarterly earnings calls and product‑development updates.
Contact information for the event is provided in the release: John Lai can be reached at (952) 405‑6216. Additional details are available on the company’s websites—petvivo.com, petvivoanimalhealth.com, and sprynghealth.com.
PetVivo issued a forward‑looking statement in the release, noting that any statements about future plans, timelines, or expectations are subject to risks and uncertainties. The company referenced its annual report on Form 10‑K for the year ended March 31, 2025, for a discussion of those risks.
Investors who wish to view the event can access the live stream on YouTube at https://www.youtube.com/live/QLFfsfCpE1U?si=ItU-PWgNUKsQ2tkQ and on LinkedIn at https://www.linkedin.com/events/7466155223904890880?viewAsMember=true. Additional company information, financial materials, and updates are available through the investor relations portal at https://www.petvivo.com/investors.
The virtual event falls on the same day as the company’s other investor‑relations activities, including a conference call for the fiscal third quarter of 2026 on Monday, February 16, 2026, and a presentation at the Market Movers Investor Summit on May 5, 2026. These events provide context for the company’s recent financial performance, which has shown growth in revenue and strategic expansion of its product line.
In summary, PetVivo Holdings is using the June 16 virtual event to give investors a detailed look at how its veterinary products are being received in the field and how the company plans to increase market penetration. The event will also highlight the company’s broader strategy of leveraging human‑derived therapies for animal health and its ongoing efforts to secure new distribution channels.
The company’s next public disclosure will likely come in the form of its fiscal third‑quarter earnings report, scheduled for release in the coming weeks. Investors will also be watching for any updates on regulatory approvals, new product launches, and potential partnership announcements that could influence the company’s valuation and market position.
